It has been reported that oxaliplatin can induce an anti-tumor immune response and immunogenic cell death, more specifically by activation of DCs, the enhancement of cross-priming of CD8- positive (CD8+) T cells, the stimulation of the anti-tumor CD4+ T cells phenotype, and down- regulation of MDSC and T-reg cells. This evidence concerns the gene CD8A and neoplasm.